Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma

Anticancer Drugs. 2003 Mar;14(3):247-50. doi: 10.1097/00001813-200303000-00009.

Abstract

Metastatic meningioma is a rare disease, which has no effective chemotherapy. We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation. A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months with near-complete resolution of metastases and disappearance of pleural fluid. The only significant toxicities observed were stomatitis and hand-foot syndrome, which resolved with dose reduction and increase of dosing intervals. Doxil was cleared very slowly in this patient with a monoexponential half-life of 108 h. The patient remains in near-complete response for 6 months after treatment discontinuation. This is the first report on an effective chemotherapy in a patient with typical metastatic meningioma. The exact mechanism accounting for such an effective drug action is not clear, but may be related to a particularly high microvascular permeability to the liposome carriers in these metastatic lesions.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Doxorubicin / therapeutic use*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Meningeal Neoplasms / drug therapy*
  • Meningeal Neoplasms / pathology
  • Meningioma / drug therapy*
  • Meningioma / secondary
  • Middle Aged
  • Pleural Effusion, Malignant

Substances

  • Antineoplastic Agents
  • Doxorubicin